Elucidation of negative regulator for lymphangiogenesis during inflammation

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K15417
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49030:Experimental pathology-related
• Research Institution: Mie University
• Principal Investigator: Kato Daisuke 三重大学, 医学部附属病院, 医員 (70887364)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: Tenascin-C / リンパ管 / negative regulator / 炎症 / インテグリン / アポトーシス

Outline of Final Research Achievements

In recent years, it has become clear that lymphatic vessels play an important role in the resolution of inflammation. Lymphangiogenic factors, including VEGF-C, have been reported, but little is known about the factors that inhibit lymphangiogenesis during inflammation. The applicant searched for a negative regulator of lymphangiogenesis during inflammation, and found that Tenascin-C, an extracellular matrix protein, inhibits lymphangiogenesis in the early stage of inflammation. Tenascin-C bound to integrin αvβ1 and induced phosphorylation of p38 MAPK, thereby suppressing proliferation and promoting apoptosis of lymphatic endothelial cells.

Free Research Field

病理

Academic Significance and Societal Importance of the Research Achievements

炎症時のリンパ管新生は、さらに炎症性疾患の治療標的として注目を浴びている。リンパ管新生のnegative regulatorについては分かっていなかったが、Tenascin-Cがnegative regulatorとして働くことがわかった。